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Urokinase-type plasminogen activator (uPA) binding to uPAR induces migration, adhesion, and proliferation through
multiple interactions with G proteins-coupled receptor FPRL1, integrins, or the epidermal growth factor (EGF) receptor
(EGFR). At least two forms of uPAR are present on the cell surface: full-length and cleaved uPAR, each specifically
interacting with one or more transmembrane proteins. The connection between these interactions and the effects on the
signaling pathways activation is not clear. We have exploited an uPAR mutant (hcr, human cleavage resistant) to dissect
the pathways involved in uPA-induced cell migration. This mutant is not cleaved by proteases, is glycosylphosphatidylino-
sitol anchored, and binds uPA with a normal Kd. Both wild-type (wt) and hcr-uPAR are able to mediate uPA-induced
migration, are constitutively associated with the EGFR, and associate with 31 integrin upon uPA binding. However,
they engage different pathways in response to uPA. wt-uPAR requires both integrins and FPRL1 to mediate uPA-induced
migration, and association of wt-uPAR to 31 results in uPAR cleavage and extracellular signal-regulated kinase (ERK)
activation. On the contrary, hcr-uPAR does not activate ERK and does not engage FPRL1 or any other G protein-coupled
receptor, but it activates an alternative pathway initiated by the formation of a triple complex (uPAR–31–EGFR) and
resulting in the autotyrosine phosphorylation of EGFR.
INTRODUCTION
The serine protease urokinase-type plasminogen activator
(uPA) and its high-affinity cell surface receptor (uPAR) play
an important role in a number of physiological as well as
pathological extracellular degradation processes, where cell
migration is required, such as inflammatory responses and
tumor invasion (Blasi and Carmeliet, 2002).
uPAR was first identified as a major player in the regula-
tion of pericellular proteolysis by modulating and concen-
trating the uPA activity at the required sites of the cell
surface (Blasi et al., 1987). However, new evidence revealed
that uPA binding to uPAR also induces proteolysis-depen-
dent and -independent intracellular signaling affecting cell
adhesion, migration, and proliferation in a variety of cells
(Chapman, 1997; Ossowski and Aguirre-Ghiso, 2000; Preiss-
ner et al., 2000; Blasi and Carmeliet, 2002; Kjøller, 2002).
uPAR is a heavily glycosylated glycosylphosphatidylino-
sitol (GPI)-anchored protein (Ploug et al., 1991) formed by
three cysteine-rich LY6-like extracellular domains (LU do-
mains D1, D2, and D3) connected by short linker regions
(Ploug and Ellis, 1994). The three consecutive three-finger
domains of uPAR are organized in an almost circular man-
ner and generate a deep internal cavity for the interaction
with uPA. The receptor-binding domain of uPA is engaged
in this central cavity, leaving the whole external surface
available for other interactions (Llinas et al., 2005). Identified
interactors include signaling molecules such as various in-
tegrins, the G protein-coupled receptor FPRL1, the epider-
mal growth factor (EGF) receptor (EGFR), the mannose-6-
phosphate receptor, the family of low-density lipoproteins
receptor-related proteins, p130, and others (Blasi and Car-
meliet, 2002).
The linker region between D1 and D2 is a protease-
sensitive region of uPAR that is cleaved by uPA produc-
ing a shorter form (D2D3), which no longer binds uPA.
Other proteases cleave the linker region producing
slightly different amino termini (Høyer-Hansen et al.,
1992, 1997; Ragno et al., 1998; Sidenius et al., 2000; Kool-
wijk et al., 2001; Andolfo et al., 2002; Beaufort et al., 2004).
The soluble form of D2D3 (s-D2D3) produced by uPA, in
particular its AVTYSRSRY amino-terminal sequence, is a
ligand for FPRL1 that induces chemotaxis (Resnati et al.,
2002). Other receptors of the family of FPRL1 (FPR and
FPRL2) have also been shown to respond to the same
peptide sequence and to be desensitized by the uPAR
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chemotactic fragments (Furlan et al., 2004; Gargiulo et al.,
2005; Selleri et al., 2005).
A second chemotactic region has been identified, in a
charged residues-rich sequence in the major loop of the
second domain of uPAR and shown to interact with v3
and 51 integrins. Its chemotactic activity is exerted
through an v3-dependent pathway involving Jak/Stat
(Degryse et al., 2005). Both chemotactic regions of uPAR are
located on the external surface of uPAR (Llinas et al., 2005).
Additional uncharacterized uPAR sequences may also be
involved in the uPAR/integrins interaction (Degryse et al.,
2005). Counterpart regions in integrins that interact with
uPAR has been previously recognized and comprise the
entire upper loop of the W4 repeat in the b-propeller region
of the  subunit of most integrins (Wei et al., 1996, 2001) and
a 1 peptide positioned nearby (Wei et al., 2005). Peptides
that span these uPAR and integrin regions are able to pre-
vent or dissociate uPAR from integrins (Wei et al., 1996,
2001, 2005; Degryse et al., 2005).
Another partner of uPAR is the EGFR. This transmem-
brane receptor coimmunoprecipitates with uPAR and can be
constitutively activated by high levels of uPAR (Liu et al.,
2002). In this case, the EGFR activation is 51 integrin
dependent, leads to the constitutive stimulation of the ex-
tracellular signal-regulated kinase (ERK) pathway and the
down-regulation of the p38 mitogen-activating protein
(MAP) kinase, determining cell proliferation in vivo. More-
over, uPA-induced migration may require ERK activation
both in the presence and in the absence of EGFR (Degryse et
al., 2001; Jo et al., 2005). In the absence of the EGFR, uPA
induces pertussis-toxin sensitive (i.e., G protein-dependent)
migration, whereas in the presence of EGFR the response is
cell proliferation (Jo et al., 2005).
Thus, uPAR can act as an adhesion, migration, and
proliferation receptor by shifting its association with its
transmembrane partners. These activities, which have
been found in cell culture, are functionally important in
vivo because uPAR is required for the migration of cells in
response to infections and inflammatory conditions, for
the mobilization of hematopoietic stem cells, and for the
growth and dissemination of tumors (Crowley et al., 1993;
Min et al., 1996; May et al., 1998; Aguirre Ghiso et al., 1999;
Gyetko et al., 2000; Aguirre-Ghiso et al., 2001; Selleri et al.,
2005). Moreover, overexpression of uPAR by cancer
and/or stromal cells is directly related to poor prognosis
in a high percentage of human cancers (Danø et al., 1999;
Sidenius and Blasi, 2003).
What is regulating uPAR association with the different
transmembrane partners? At least three different forms of
uPAR can be present on the cell surface: monomeric
uPAR, dimerized uPAR, and cleaved uPAR (Høyer-Han-
sen et al., 1992; Cunningham et al., 2003). Each of these
forms can have specific localization, transmembrane part-
ners, and activity. In this article, we focused on uPA-
induced cell migration and used a human uncleavable
mutant of uPAR (hcr-uPAR) to shift the pool from cleaved
to full length and differentiate between the various activ-
ities. We have determined the existence of individual
pools of uPAR associated with specific transmembrane
receptors, and the dynamic changes occurring upon bind-
ing of uPA. Moreover, the presence of unique activities
associated with the hcr-mutant indicate that different
forms and/or conformations of uPAR may select different
signaling pathways.
MATERIALS AND METHODS
Reagents
Human two-chain uPA was obtained from Areta International (Varese, Italy),
courtesy of Dr. M. Nolli. The amino-terminal fragment (ATF) of human uPA
was a kind gift of J. Henkin (Abbott Laboratories, Abbott Park, IL). Produc-
tion and purification of D2D388-274 was described previously (Fazioli et al.,
1997). The murine monoclonal anti-human uPAR antibodies R2 and R3
(Rønne et al., 1991) and the rabbit polyclonal anti-human uPAR antibody were
kindly provided by Drs. E. Rønne and G. Høyer-Hansen (Finsen Laboratory,
Copenaghen, Denmark) and purified through a MAbTrap (GE Healthcare,
Little Chalfont, Buckinghamshire, United Kingdom). The rabbit anti-human
uPAR polyclonal serum has been described previously (Resnati et al., 1996).
The MMK1 has been described previously (Klein et al., 1998). Irrelevant rabbit
and mouse (MOPC-21) IgG, the synthetic chemotactic peptide formyl-
methyonil-leucyl-proline (fMLP), the phosphorylated (p)-ERK inhibitor
PD98059, and phosphatidylinositol-specific phospholipase C (PI-PLC) were
purchased from Sigma-Aldrich (St. Louis, MO). Peptides 325 (PRHRHM-
GAVFLLSQEAG) and s325 (HQLPGAHRGVEARFSML) were synthesized by
PRIMM (Milan, Italy). Recombinant pertussis toxin (PTX) was a generous gift
of Dr. M. G. Pizza (Chiron, Siena, Italy). The p-c-Jun NH2-terminal kinase
(JNK) inhibitor SP600125 was kindly provided by Prof. M. Del Rosso (Uni-
versity of Firenze, Florence, Italy). EGF was a generous gift of Dr. L. Beguinot
(H. S. Raffaele, Milan, Italy). Tyrphostin AG1478, a p-EGFR inhibitor was
from Calbiochem (San Diego, CA). FuGENE and N-glycosidase F were from
Roche Diagnostics (Indianapolis, IN). The anti-FPRL1 polyclonal antibody
(antibody N77) was generated as described previously (Furlan et al., 2004).
Monoclonal anti-murine 3 and 5 integrins, polyclonal anti-EGFR, and
monoclonal anti-total ERK2 antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA). Monoclonal anti-mouse 1 integrin antibody was from
Chemicon International (Temecula, CA). Monoclonal anti-phosphotyrosine
antibody was from Upstate Biotechnology (Lake Placid, NY), and a polyclonal
antibody that specifically detects phosphorylated ERK1 and ERK2 was from
Cell Signaling Technology (Beverly, MA). Horseradish peroxidase-conjugated
antibodies specific for mouse IgG and rabbit IgG were from GE Healthcare.
Cell Lines and Culture Conditions
Murine fibroblast cell line LB6 were grown in DMEM (Invitrogen, Milan,
Italy) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and peni-
cillin-streptomycin-glutamine (Invitrogen) at 37°C with 5% CO2. LB6 clone 19
cells, expressing the wild-type human uPAR (Roldan et al., 1990), were grown
in the same medium, supplemented with 0.5 mg/ml Geneticin (G418; Invitro-
gen). LB6 clones hcr16 and hcr15 were grown in the same medium, supple-
mented with 250 g/ml hygromycin (Roche Diagnostics, Milan, Italy).
Generation of Stable Transfected hcr-uPAR Clones
The construction of the expression vector encoding for the human cleavage-
resistant uPAR mutant (hcr-uPAR) was described previously (Liu et al., 2002).
Proteases cleavage sites in the linker region between domain 1 and 2 were
abolished by mutating R83K, Y87C, R89K, and R19K as described. LB6 cells
were transfected with the hcr-uPAR construct using FuGENE under recom-
mended conditions. Stably transfected cells were selected with hygromycin
(100 g/ml), and isolated clones were maintained in 100 g/ml hygromycin.
hcr-uPAR expression and cleavage resistance was determined by Western blot
analysis on total cell extracts after deglycosylation as described below.
Cell Extracts, Western Blot Analysis, and
Immunoprecipitation (IP)
Cell lysates were cleared by centrifugation at 15,000 rpm for 10 min at 4°C and
quantitated by Bio-Rad protein assay (Bio-Rad, Hercules, CA). Equal amounts
of each extract (50–80 g) were then subjected to SDS-PAGE and electro-
transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA)
for direct immunoblotting. The membrane was incubated in blocking solution
(Tris-buffered saline [TBS] containing 5% nonfat dried milk and 0.05% Tween
20) for 1 h at room temperature followed by 1 h of incubation with the
indicated antibodies, three washes in TBS containing 0.05% Tween 20, and 1 h
of incubation with donkey anti-rabbit horseradish-peroxidase-linked F(ab)2
fragment (1:5000; GE Healthcare). Proteins were detected using an enhanced
chemiluminescence method according to the manufacturer’s instructions
(Pierce Chemical, Rockford, IL). For the detection of full-length and cleaved
human uPAR, total cell extracts were first subjected to deglycosylation. Ten
microliters of cell extracts containing 0.5% SDS and 2 mM dithiothreitol were
incubated at 95°C for 3 min. Proteins were deglycosylated by addition of 20
l of deglycosylation buffer (phosphate-buffered saline [PBS] containing 0.5%
Triton X-100 and 15 mM EDTA) containing 1 U of N-glycosidase F and
incubated at 37°C for 2 h. Deglycosylated samples were analyzed by SDS-
PAGE under reducing conditions.
Where indicated, cells were pretreated with proteinases inhibitors (50 M
ilomastat, 80 M E-64, 100 nM aprotinin, and 100 mol/l amiloride) for 2 h
and then treated with 10 nM uPA for the indicated times in the presence or in
the absence of the same inhibitors.
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For IP, total protein (0.5–1,5 mg) was precleared in PBS containing protein
G agarose for 1 h at 4°C, and the supernatant was incubated with antibodies
against murine EGFR or 3 integrin (1 g/ml in PBS) overnight at 4°C. After
washing with PBS, the immunoprecipitates were analyzed by Western blot-
ting using the indicated antibodies.
Chemotaxis Assay
Migration of LB6 parental cell line and LB6 stable transfected clones was
assessed by 48-well microchemotaxis chamber (Neuro Probe, Gaithersburg,
MD). Chemoattractants (26 l), at different concentrations in serum-free
DMEM medium, were placed in the bottom compartment of the chamber, and
a 200 l of cell suspension (125,000 cells/ml) was added to the top compart-
ment. The two compartments were separated by a fibronectin-coated (10
g/ml) 8-m-pore size polycarbonate filter (Neuro Probe) and incubated at
37°C in humidified air with 5% CO2 for 5 h. The filter was removed, scraped,
and stained with Diff-Quik (Dade Diagnostics, Aguada, Puerto Rico), and
migrated cells were counted by light microscopy. Results expressed as the
mean  SD from triplicates samples are representative of at least three
experiments. Migration in the absence of chemoattractant was set to 100%.
Potential inhibitors of migrations (i.e., peptides, desensitizers, and pathway
inhibitors) were preincubated with cells for 30 min at 37°C, and the assay was
performed as described above.
Flow Cytometry
Cells (5  105) resuspended in 100 l of staining buffer (PBS containing 2%
fetal calf serum [FCS]) were incubated with the anti-human uPAR R2 anti-
body for 30 min on ice. Cells were washed with ice-cold staining buffer and
resuspended in 100 l of staining buffer containing Alexa 488-conjugated
F(ab)2 fragment of goat anti-mouse IgG (Invitrogen). After 30 min on ice, cells
were washed with PBS, resuspended in 500 l of PBS, and analyzed using a
FACScan flow cytometer (BD Biosciences Italia, Milan, Italy). Dead cells were
excluded from the analysis based on the forward and sideways light-scatter-
ing proprieties. Negative controls were provided by incubation with an
irrelevant isotype-matched mouse antibody (MOPC-21), followed by staining
with the same Alexa 488-conjugated secondary F(ab)2 fragment of goat
anti-mouse IgG.
When appropriate, human wild-type (wt)- and hcr-uPAR-expressing cells
were incubated at a density of 106/ml in DMEM with 25 mM HEPES, pH 7.4,
in the presence or in the absence of PI-PLC (5 U/ml) for 1 h at 37°C, as
described previously (Ploug et al., 1991).
Ligand Binding Assay
Subconfluent cell monolayers, plated into 24-well plates the day before assay,
were washed twice with PBS and incubated with increasing concentrations of
125I-ATF (0.01–336 nM) (iodogen; Pierce Chemical), diluted in binding buffer
(DMEM, 1% bovine serum albumin, and 20 mM HEPES) for 30 min at 4°C in
the absence or in the presence of 100-fold excess of unlabeled uPA. After three
washes with 1 ml of binding buffer, cells were lysed with 100 l of NP-40 lysis
buffer (150 mM NaCl, 1% NP-40, and 50 mM Tris-HCl, pH 8.0). Lysates were
collected and counted in a gamma counter. Binding in the presence of 100-
fold excess of unlabeled uPA was subtracted.
RESULTS
Properties of the Uncleavable hcr-uPAR
To investigate the role played by uPAR cleavage in uPA-
mediated cell migration, a mutated form of the human
uPAR (Liu et al., 2002) was used (Figure 1A). Four different
amino acids substitutions were introduced to mutate all
known cleavage sites located in the linker region between
D1 and D2, thus generating a human cleavage-resistant (hcr)
form of uPAR. The minimum chemotactically active region
SRSRY (Fazioli et al., 1997) is mutated in the two arginines,
although the essential (Trigwell et al., 2000) tyrosine is still
intact. Murine LB6 cells that do not produce uPA and have
a low level of endogenous murine receptor (Sidenius and
Blasi, unpublished data) were stably transfected with hcr-
uPAR, and two expressing clones were selected. A stably
transfected and well characterized clone expressing wild-
type human uPAR (LB6 cl19) was already available (Roldan
et al., 1990; Riittinen et al., 1996).
Expression and cell surface localization of human wt-
uPAR and hcr-uPAR were verified by cytofluorimetric anal-
ysis with the specific anti-uPAR antibody R2, using un-
treated or PI-PLC-treated cells. PI-PLC releases all GPI-
anchored proteins from plasma membrane, including uPAR
(Ploug et al., 1991). The level of uPAR expression evaluated
by cytofluorimetry was very similar in both transfected
clones and was reduced by PI-PLC treatment (data not
shown).
hcr-uPAR was also characterized for its ability to bind
uPA using iodinated human ATF (the receptor binding,
catalytically inactive fragment of uPA). Binding of ATF to
both uPA receptors was saturable and specific because it
was displaced by unlabeled human uPA. The three clones
expressed comparable levels of surface receptors and bound
uPA with about the same affinity (Kd of 1.2–2.4 nM) (data
not shown).
We confirmed that hcr-uPAR was not cleavable by ana-
lyzing total cell extracts after deglycosylation and under
reducing conditions by immunoblotting. LB6 cells stably
transfected with the human wt-uPAR cDNA (cl19) and
grown in the presence of 10% serum spontaneously generate
a truncated form of uPAR that has the same molecular
weight as the D2D3 form of uPAR (Figure 1B). The fraction
of cleaved wt-uPAR varies between 10 and 50% of total
uPAR depending on the culturing conditions (data not
shown). Because LB6 cells produce no uPA, the cleavage of
uPAR in the wt-uPAR cells in the absence of exogenous uPA
must be due to a different protease. No cleaved uPAR was
seen in the total cell extracts of hcr-uPAR cells (Figure 1B,
left), nor was it cleaved upon addition of exogenous uPA
(Figure 1B, right), a condition that led to an efficient cleavage
of wt-uPAR.
Figure 1. The human cleavage-resistant uPAR. (A) Schematic rep-
resentation of wt-uPAR and hcr-uPAR. The amino acid sequence of
the linker region between domains 1 and 2 is reported. The core
sequence of the chemotactic epitope is underlined. Mutated resi-
dues in hcr-uPAR are marked by asterisk (*). Arrows indicate pro-
teolytic cleavage sites and the signaling residue Tyr92. (B) Trans-
fected clones showed a cell surface staining drastically reduced by
PI-PLC treatment. Cells preincubated in the absence or in the pres-
ence of PI-PLC (1 U/ml) were stained with the monoclonal anti-
uPAR antibody R2. Cell surface staining was verified by cytofluo-
rimetric analysis. (C) Analysis of uPAR cleavage under culturing
conditions (10% FCS, left) or after addition of exogenous human
uPA (10 nM, right). Samples were deglycosylated and analyzed by
Western blotting using a rabbit polyclonal anti-human uPAR anti-
body. Positions of intact (uPAR) and cleaved (D2D3) uPAR are
indicated.
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Effects of the hcr Mutation on uPA-dependent and
Unstimulated Cell Migration
Because it has been established that uPA/uPAR interactions
are strictly species specific (Appella et al., 1987; Estreicher et
al., 1989), murine uPAR is incapable of binding human uPA
and thus LB6 parental cells do not display a chemotactic
response to human uPA (Resnati et al., 1996) (Figure 2A).
However, when stimulated with either an uPAR fragment,
which contains the specific chemotactic epitope, 0.1 mM
fMLP, which activates the same receptor as the uPAR che-
motactic fragment or upon transfection with wild-type (wt)
human uPAR and human uPA stimulation migration was
induced, indicating that uPAR-mediated signaling is intact
in these cells (Resnati et al., 1996; Fazioli et al., 1997). To test
whether uPAR cleavage was necessary for cell migration,
wt-uPAR and hcr-uPAR-expressing clones were analyzed
for their ability to migrate on fibronectin in response to a
human uPA gradient using a modified Boyden chamber
assay. Incubation of wt-uPAR cells with human uPA in-
duced, as expected, a dose-dependent chemotactic response,
with a maximal effect at 10 nM. A similar chemotactic re-
sponse was also observed in hcr-uPAR-expressing cells. No
migration was induced by uPA in LB6 parental cells (Figure
2A). All cells equally responded to 0.1 mM fMLP, used as
positive control.
To verify that the chemotactic response in both cell lines
was because of a specific interaction between human uPA
and human uPAR, cells were pretreated with either anti-
uPAR monoclonal antibodies (R3) or with an equal amount
of control monoclonal IgGs (MOPC-21). By recognizing an
epitope localized on D1, R3 is able to block uPA binding to
uPAR (Rønne et al., 1991). Addition of R3 completely
blocked uPA-induced cell migration in both wt- and hcr-
uPAR-expressing cells (Figure 2B). Together, these results
show that both wt and hcr forms of uPAR mediate migration
in response to uPA, suggesting that mutations in the linker
region of uPAR that prevent its proteolytic cleavage do not
block the ability of uPAR to mediate cell migration upon
uPA stimulation.
Differential uPA/uPAR Signaling in wt- Versus hcr-uPAR-
expressing Cells
The data presented in Figure 2A show that uPA-induced
migration occurs both in the presence and in the absence of
uPAR cleavage. However, the basal migration of the cells
expressing the two forms of uPAR was different: the basal
migration of both hcr-uPAR clones was similar to that of
parental LB6 cells, whereas cl19, as expected, showed a
substantially higher basal migration (data not shown). We
therefore wondered whether wt-uPAR and hcr-uPAR use
the same pathways to mediate cell migration.
Previous work established that uPAR interaction with
integrins plays a role in uPA-induced migration (Wei et al.,
1996). We first tested the involvement of 31 and 51
integrins, as they are well characterized transmembrane
adaptor protein for uPAR (Wei et al., 2001). To test the
interactions, we used a synthetic peptide, 325, a 17-mer
derived from the 3 integrin sequence shown to block
uPAR/31 and uPAR/51 interactions (Wei et al., 2001).
uPAR/31 interaction was verified by immunoblotting
analysis after immunoprecipitation with an anti-3 antibody
in cells incubated with increasing concentrations of uPA. As
shown in Figure 3A, incubation with uPA very strongly
enhanced the interaction of both wt- and hcr-uPAR with the
31 integrin, and the effect was dose dependent. The re-
sponse of wt-uPAR to low concentration of uPA (1 nM) was
appreciably stronger than that of hcr-uPAR. The uPAR/in-
tegrin interaction was inhibited in the presence of 325 but
not of a scrambled version of the peptide (s325). Moreover,
only the full-length form of uPAR, and not D2D3, was found
to associate with 3-integrin. Similar expression levels of
both 31 and other integrins (51 and v3) were ob-
served in parental LB6 cells and in all transfected clones by
immunoblotting analysis on total cell extracts (data not
shown).
To investigate the role of uPAR/31 interaction on wt-
and hcr-uPAR-mediated cell migration, chemotaxis experi-
ments were carried out in the absence or in the presence of
either 325 or s325. Addition of 325, but not of s325,
strongly suppressed uPA chemotaxis, but it had no effect on
FCS-induced chemotaxis in both wt-uPAR and hcr-uPAR
cells (Figure 3B). Thus, both wt-uPAR and hcr-uPAR are
interacting with the 31 integrin, and this interaction is
required to mediate uPA-induced cell migration.
We next tested whether cells expressing wt-uPAR or hcr-
uPAR differed in the engagement of a second well-charac-
terized transmembrane adaptor of uPAR, FPRL1 (Resnati et
al., 2002). Because high concentrations (0.1 mM) of fMLP
induce migration of LB6 cells (Figure 2A), these cells are
Figure 2. uPA-induced and uPAR-mediated migration of wt- and
hcr-uPAR-expressing cells. (A) Chemotactic response of LB6 paren-
tal and transfected cells to human uPA. Cells migrated toward
medium alone (control), fMLP (108 M), or increasing concentra-
tions of human uPA (1, 10, and 50 nM). Random cell migration (c)
of each cell line is referred to as 100% of migration. The data
represent the average of nine independent experiments each in
triplicates. *p  0.0014, **p  0.0013, ***p  0.87830 (Student’s t
test). (B) Addition of R3 (monoclonal anti-uPAR antibody blocking
uPA binding to uPAR) blocks uPA-induced migration of both wt-
and hcr-uPAR-expressing cells. Cells migrated toward medium
alone (c), uPA (10 nM), or uPA plus either R3 or irrelevant mouse
IgGs (MOPC). Random cell migration (c) of each cell line is referred
to as 100% of migration. Results are representative of three inde-
pendent experiments.
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likely to express FPRL1. To verify the presence of FPRL1 (in
the absence of an anti-murine FPRL1 antibody), we tested
the chemotactic response of LB6 cells to increasing concen-
trations of the synthetic MMK1 peptide, a specific, high-
affinity agonist for FPRL1 (Klein et al., 1998). MMK1 induced
dose-dependent migration in all uPAR-expressing clones as
well as in parental LB6 cells (data not shown). FPRL1 de-
sensitization experiments by MMK1 pretreatment were then
performed to verify FPRL1 involvement in uPA-induced
migration. As shown in Figure 4A, MMK1 pretreatment
completely suppressed uPA- and MMK1-, but not FCS-in-
duced chemotaxis in wt-uPAR-expressing cells. However,
desensitization of FPRL1 did not block uPA-induced migra-
tion in hcr-uPAR cells. We verified that all clones activated
the FPRL1 pathway because they all were sensitive to sD2D3
that contains the amino-terminal chemotactic sequence, and
to MMK1 desensitization (data not shown), as reported pre-
viously (Resnati et al., 2002).
Because uPA-induced migration in hcr-uPAR-expressing
cells was not inhibited by MMK1-desensitization, we tested
whether G-coupled receptors different from FPRL1 were
involved in uPA-dependent hcr-uPAR-mediated migration
using the ADP-ribosylating PTX. The inhibitory effect of
PTX is an indication of the involvement of heterotrimeric
Gi/o proteins in the signaling pathway (Baggiolini et al.,
1994; Neer, 1995). As expected, PTX efficiently blocked uPA
and MMK1, but not FCS-induced migration in wt-uPAR-
expressing cells (Figure 4B). On the contrary, no effect was
seen on uPA-induced migration with hcr-uPAR-expressing
cells, whereas the activity of MMK1 was still inhibited. This
result indicates that a signaling pathway not involving a G
protein-coupled receptor is activated by uPA in hcr-uPAR
cells. We conclude that the mutations introduced in hcr-
uPAR prevent the choice of the FPRL1 pathway.
To identify the alternative pathway engaged by hcr-uPAR,
we explored another partner of uPAR: the EGF receptor (Liu
et al., 2002; Jo et al., 2005). Both wt- and hcr-uPAR-expressing
cells have similar levels of EGFR (Figure 5B). To probe the
functional role of the EGFR, we tested the effect of the
EGFR-specific inhibitor tyrphostin (AG1478) on uPA-depen-
dent migration. As shown in Figure 5A, tyrphostin AG1478
completely blocked uPA-induced migration of hcr-uPAR
cells but did not affect that of wt-uPAR-expressing cells. The
effect was specific because AG1478 did not inhibit FCS-
induced migration (which depends on the presence of a
variety of serum factors). These results confirm that the two
forms of uPAR engage two completely different pathways:
wt (cleavable)-uPAR involves the FPRL1 pathway, whereas
the cleavage-resistant uPAR involves the EGFR signaling
pathway. We therefore tested for uPA-mediated EGFR ty-
rosine-phosphorylation in both wt-uPAR and hcr-uPAR
cells. As shown in Figure 5B, uPA induced a strong phos-
phorylation of the EGFR only in the hcr-uPAR-expressing
cells, which also have a higher basal level of p-EGFR. No
EGFR phosphorylation was observed in wt-uPAR-express-
ing cells after addition of uPA. We can therefore conclude
that the two forms of uPAR activate two different types of
cell surface adaptor proteins. The lack of activation of EGFR
by uPA in wt-uPAR LB6 cells may seem in contradiction
with previous reports (Liu et al., 2002). However, the exper-
iments reported in the present study are carried out in very
different cells. LB6 are mouse cells, do not express uPA and
have very low levels of endogenous murine uPAR (that does
not bind human uPA), and have been transfected with hu-
man uPAR. Moreover, uPAR has been shown to be able to
signal through different pathways in different cells (Jo et al.,
2003, 2005).
The lack of G protein coupled receptor involvement and
the activation of the EGFR in hcr-uPAR-mediated migration
prompted an inquiry into the downstream signaling path-
ways of the wt- and hcr-uPAR cells. The involvement of two
members of the MAP kinase family, ERK and JNK, was
tested. wt- and hcr-uPAR-expressing cells were induced to
migrate by uPA alone or uPA and either the mitogen-acti-
vated protein kinase kinase (MEK) inhibitor PD98059 or the
JNK inhibitor SP600125. As shown in Figure 6A, the MEK
inhibitor prevented both basal and uPA-induced migration
of wt-uPAR-expressing cells but had no effect on hcr-uPAR-
expressing cells. No inhibition was observed with the
SP600125 JNK inhibitor (Figure 6B). We can, therefore, ex-
clude an involvement of JNK and conclude that wt-uPAR
and hcr-uPAR respond to uPA by activating different down-
stream signaling pathways. The inhibitory activity of
PD98059 and SP600125 was verified by immunoblotting
analysis after treatment of both wt- and hcr-uPAR cells with
uPA. Both inhibitors efficiently reduced the basal levels of
active ERK and JNK (Figure 6C). Moreover, PD98059 com-
pletely blocked the uPA-induced phosphorylation of ERK,
which only occurs in the wt-uPAR-expressing cells (Figure
6C). Interestingly, Figure 6A shows that PD98059 also inhib-
ited the basal migration of wt-uPAR-expressing cells, but
not of hcr-uPAR-expressing cells. In fact, wt-uPAR cells have
Figure 3. Integrins involvement in uPA-induced migration of wt-
and hcr-uPAR-expressing cells. (A) uPAR/31 association is uPA
dependent for both forms of uPAR, and addition of 325 inhibits
this association. Cells were pretreated for 20 min at 37°C with 325
or s325 peptides (10 M) and incubated for an additional hour with
the indicated concentrations of uPA. 3-Integrin was immunopre-
cipitated from total cell extracts using an anti-3 antibody. Immu-
noprecipitates were blotted for uPAR (bottom) and 3 (top). (B)
325 peptide specifically blocks uPA-induced migration in both wt-
and hcr-uPAR-expressing cells. Cells were preincubated (20 min at
37°C) with 325 or s325 peptides (10 M), and their chemotactic
responses were tested toward medium alone (c), uPA (10 nM), or
FCS (2%). Random cell migration (c) of nonpretreated cells is re-
ferred to as 100% of migration. Results are representative of three
independent experiments.
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a higher basal migration and a higher level of active ERK
than hcr-uPAR cells (data not shown).
wt-uPAR and ERK Activation
wt-uPAR-expressing cells respond to uPA by engaging both
integrins and FPRL1 (see above). To investigate which of
these two transmembrane receptors was responsible for
ERK activation in wt-uPAR cells, we performed a desensi-
tization experiment with MMK1 and then induced the cells
to migrate with uPA or sD2D3, which also is an agonist of
FPRL1 (Resnati et al., 2002). As shown in Figure 7A, sD2D3
did not (or only marginally) activate ERK1/2 and the MMK1
pretreatment did not inhibit uPA-dependent ERK phosphor-
ylation. Therefore, uPA-induced ERK phosphorylation was
not achieved through FPRL1 activation. Moreover, addition
of 325, but not of s325, to wt-uPAR cells inhibited uPA-
induced phosphorylation of ERK (Figure 7B). The uPAR/in-
tegrins association is therefore necessary to activate ERK.
These data suggest that in the case of wt-uPAR at least two
pathways are activated upon uPA binding, one engaging
FPRL1 and the other resulting in ERK activation. Both path-
ways are required for the induction of cell migration by
uPA.
In addition, as shown in Figure 7C, integrins are involved
in wt-uPAR cleavage because addition of 325, but not of
s325, inhibited uPA-induced cleavage of uPAR. However,
integrins are not required for the activation of FPRL1 (at
least by sD2D3), because no inhibition of sD2D3-induced
migration was seen in the presence of 325 (Figure 7D).
Although soluble cleaved uPAR is known to activate FPRL1
(Resnati et al., 2002), no data are available about the ability of
GPI-anchored uPAR to interact and/or activate FPRL1.
Therefore, it remains to be established whether integrin-
mediated uPAR cleavage activates FPRL1, ERK, or both
pathways (see below).
The EGFR and hcr-uPAR Signaling
The next step was to analyze the role played by integrins in
the EGFR pathway. As shown in Figure 8A, uPAR was
coimmunoprecipitated by anti-EGFR antibodies in both wt-
and hcr-uPAR cells. Only the full-length wild-type uPAR
was found associated with the EGFR and addition of either
uPA or 325 had no effect on both wt- and hcr-uPAR. Thus,
the uPAR/EGFR association is integrin independent. How-
ever, the strong uPA-induced EGFR tyrosine phosphoryla-
Figure 4. FPRL1 involvement in uPA-induced migration of wt-uPAR-expressing cells. (A) MMK1 specifically desensitizes uPA-induced
chemotaxis in wt- but not hcr-uPAR-expressing cells. As controls, desensitization of FCS- and MMK1-induced migration (Resnati et al., 2002)
is shown. For desensitization, cells were preincubated for 30 min at 37°C with MMK1 (106 M), and their chemotactic responses were tested
toward medium alone (c), uPA (10 nM), MMK1 (106 M), or FCS (2%). Random cell migration (c) of nonpretreated cells is referred to as 100%
of migration. Results are representative of three independent experiments. (B) Pertussis toxin specifically blocks uPA-induced migration in
wt- but not hcr-uPAR-expressing cells. Cells were preincubated for 30 min at 37°C with pertussis toxin (100 ng/ml), and their chemotactic
responses were tested toward medium alone (c), uPA (10 nM), MMK1 (106 M), or FCS (2%). Random cell migration (c) of nonpretreated cells
is referred to as 100% of migration. Results are representative of three independent experiments.
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tion (as shown only in hcr-uPAR cells by immunoblotting
with anti-p-tyrosine antibodies; Figure 5A) was completely
inhibited by 325, thus showing the involvement of inte-
grins in the activation of this pathway (Figure 8B).
We also investigated whether uPAR, 31 integrin, and
EGFR can associate into a ternary complex. We immunopre-
cipitated extracts from untreated and uPA-treated wt-uPAR
and hcr-uPAR cells with anti 3 integrin antibodies and
tested for the coprecipitation of uPAR and EGFR. As shown
in Figure 8C (and previously in Figure 3A), uPAR associa-
tion with the integrins was dependent on uPA in both cells.
On the other hand, the association of the uPAR/31 com-
plex with the EGFR occurred only in hcr cell extracts and
was strongly increased by uPA.
Timing and Protease Dependence in uPA/uPAR Signaling
Last, to further analyze the relationship between signaling
and cleavage, we compared the timing of activation of ERK
and EGFR with that of uPAR cleavage upon addition of
exogenous uPA. As shown in Figure 9A, wt-uPAR cleavage
was visible already after 5–10 min and increased at least up
to 60 min, at which time residual full-length uPAR was still
present. The same time course was observed for ERK acti-
vation. To verify the cause–effect nature of this correlation,
two different approaches were used. First, we added the
catalytically inactive ATF. However, as shown in Figure 9A,
addition of ATF resulted in abundant cleavage of uPAR and
ERK activation, showing that ligand binding is sufficient to
achieve uPAR cleavage by proteases other than uPA and
that again cleavage is associated with ERK activation. Sec-
ond, we added uPA in the presence of a cocktail of protease
inhibitors (50 M ilomastat, 80 M E-64, 100 nM aprotinin,
and 100 mol/l amiloride). As shown in Figure 9B, the use
of a cocktail of protease inhibitors supported the require-
ment of uPAR cleavage for uPA-dependent ERK activation,
because inhibition of the cleavage in wt-uPAR-expressing
cells correlated with the inhibition of uPA-mediated ERK
phosphorylation. On the other hand, in hcr-uPAR-express-
ing cells, as shown in Figures 1C and 6C, there was no
evidence of uPAR cleavage or of ERK activation; the EGFR
phosphorylation started 20 min after uPA addition. Surpris-
ingly, ATF did not induce EGFR phosphorylation in these
cells (Figure 9A). However, these data correlate well with
the migration data. In fact, although ATF efficiently induced
migration of wt-uPAR cells, no migration was observed with
hcr-uPAR-expressing cells (data not shown). No phosphor-
ylation of EGFR at any time point and with any treatment
was observed in wt-uPAR-expressing cells. Together, these
data indicate that ERK phosphorylation requires uPAR
cleavage, whereas EGFR activation correlates with the lack
of uPAR cleavage.
DISCUSSION
The use of a mutated uPAR (hcr-uPAR) has allowed the
dissection of pathways through which uPAR can stimulate
cell migration in LB6 cells (Figure 10).
The data presented show that the two forms of uPAR
engage two completely different pathways. Both forms of
uPAR are constitutively associated with the EGFR. Upon
uPA stimulation, an EGFR-free pool of wt-uPAR or wt-
uPAR dissociating from the EGFR, associate with 31. On
the contrary, in hcr-uPAR cells a ternary 31–uPAR–EGFR
complex is formed upon uPA addition. Moreover, in wt-
uPAR, association to integrins is required to cleave uPAR
and to activate two distinct but necessary pathways: FPRL1
and ERK pathways. On the contrary, hcr-uPAR, which does
not activate ERK and does not engage FPRL1 or any other G
protein-coupled receptor (GPCR), activates an alternative
pathways initiated by the phosphorylation of the EGFR.
We have previously demonstrated that a G protein-cou-
pled receptor (FPRL1) of the family of the FPR receptors,
connected to an heterotrimeric Gi protein, functions as a
transmembrane adapter upon either uPA or ATF binding to
uPAR and can directly interact with the cleaved soluble
form of uPAR sD2D3 (Resnati et al., 2002; Furlan et al., 2004).
FPRL1 mediates migration by recognizing a chemotactic
epitope of uPAR, located between the first and second do-
main and characterized by the sequence AVTYSRSRY (Fa-
zioli et al., 1997; Nguyen et al., 2000; Resnati et al., 2002).
Through this interaction, a signaling pathway is activated
that includes a src-like kinase and ERK, both required for
migration (Resnati et al., 1996; Degryse et al., 1999; Webb et
al., 2000). The chemotactic fragment can not only be gener-
ated by its ligand uPA (Høyer-Hansen et al., 1992, 1997) but
also by other proteases such as plasmin, cathepsin G, matrix
metalloproteases, and neutrophil elastase (Høyer-Hansen et
al., 1997; Koolwijk et al., 2001; Andolfo et al., 2002; Beaufort
Figure 5. EGFR involvement in uPA-induced migration of hcr-
uPAR-expressing cells. (A) The EGFR-inhibitor AG4178 specifically
blocks uPA-induced migration in hcr- but not wt-uPAR-expressing
cells. Cells were preincubated for 30 min at 37°C with AG4178 (50
nM), and their chemotactic responses were tested toward medium
alone (c) or uPA (10 nM). Random cell migration (c) of nonpre-
treated cells is referred to as 100% of migration. Results are repre-
sentative of three independent experiments. (B) uPA induces phos-
phorylation of EGFR in hcr- but not wt-uPAR-expressing cells. After
20-min stimulation with uPA, cell extracts were prepared and sub-
jected to immunoprecipitation with an antibody against EGFR fol-
lowed by immunoblot analysis to detect phosphorylated EGFR
(p-Tyr) and total EGFR.
Alternative Signaling through uPAR
Vol. 17, January 2006 373
et al., 2004). In fact, the present data also show that binding
of the catalytically inactive ATF can still stimulate uPAR
cleavage in the absence of uPA. FPRL1 activation seems to
be caused by direct binding of the uPAR chemotactic
epitope exposed by either ligand-induced conformational
change, or proteolytic cleavage (Resnati et al., 1996, 2002).
hcr-uPAR is not cleaved by endogenous proteases nor by
exogenous uPA (Figure 1C). Starting from its amino-termi-
nal end, the first two mutations modify Arg83, a key residue
for uPA cleavage, and Tyr87, cleavage site for chymotrypsin.
These mutations lie outside the chemotactic region (which
starts at residue 84) and are apart from the core sequence
SRSRY starting at residue 88. The two other mutations lie
within the core sequence SRSRY (Arg89 and Arg91). The
first is not conserved in other species, but the peptide nev-
ertheless still has chemotactic activity. Most importantly,
residue Tyr92, an essential residue for signaling in this se-
quence (Trigwell et al., 2000) has not been mutated (Figure
1A). So far, no information is available on the role of Arg91.
Because the amino acids substitutions are largely conserva-
tive, it was not unexpected that hcr-uPAR was normally
expressed on the cell surface, could be released by PI-PLC,
indicating GPI anchoring (Figure 1B), and could bind its
ligand ATF with essentially a normal affinity. Despite being
uncleavable by uPA, hcr-uPAR was still able to transduce
the uPA chemotactic signal with essentially the same effi-
ciency as wt-uPAR (Figure 2A). Moreover, both receptors
are constitutively associated with the EGFR (Figure 8A) and
are induced to associate to 31 integrin upon uPA binding
(Figure 3A). In spite of these similarities, however, the func-
tional outcome of these interactions was different. Only in
the hcr-uPAR cells uPA addition resulted in the formation of
a ternary complex containing 31, uPAR, and EGFR (Fig-
ure 8C) and in the activation of the EGFR (Figures 5B, 8B,
and 9A). This suggests that the wt- and hcr-uPAR have a
different conformation or that other unidentified proteins
Figure 6. MAP kinases involvement in
uPA-induced migration of wt- and hcr-uPAR-
expressing cells. The ERK inhibitor PD98059
specifically blocks uPA-induced migration in
wt- but not hcr-uPAR-expressing cells (A),
whereas the JNK-inhibitor SP600125 has no
effect (B). wt- and hcr-uPAR-expressing cells
were induced to migrate toward an uPA gra-
dient in the presence or in the absence of
either PD98059 (50 M) or SP600125 (50 M).
Random cell migration (c) of nonpretreated
cells is referred to as 100% of migration. Re-
sults are representative of three independent
experiments. (C) The inhibitory activity of
PD98059 and SP600125 was verified by West-
ern blotting after treatment of both wt- and
hcr-uPAR cells with uPA. Both inhibitors ef-
ficiently reduced the basal levels of active
ERK and JNK. Moreover, PD98059 com-
pletely blocked the uPA-induced phosphory-
lation of ERK which occurs only in the wt-
uPAR cells.
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participate in the complexes assembled by the two forms of
uPAR, causing differential activation of EGFR. Although
understanding the molecular mechanisms behind the acti-
vation of the EGFR will require further investigations, the
recent report of the crystal structure of uPAR and the mod-
eling of its interaction with uPA (Llinas et al., 2005) shows
that the formation of a quadruple complex containing uPAR,
uPA, 31-integrin, and EGFR is possible and would not be
prevented by uPA binding, because uPA binds to an internal
cavity leaving the large external surface of the folded protein
Figure 7. wt-uPAR/31 association, but not FPRL1 activation, is required to activate ERK. (A) MMK1 desensitization does not inhibit
uPA-induced ERK phosphorylation, and stimulation with sD2D3 does not induced ERK phosphorylation. For desensitization, cells were
preincubated for 30 min at 37°C with MMK1 (106 M) and treated with medium alone (c), uPA (10 nM), or sD2D3 (1 nM) for additional 40
min. Total cell extracts were analyzed by Western blot using an anti-phosphorylated ERK (p-ERK1/2) and an anti-total ERK (tot-ERK2)
antibody. (B) 325 peptide specifically blocks uPA-induced phosphorylation of ERK. Cells were pretreated for 20 min at 37°C with 325 or
s325 peptides (10 M) and incubated for 40 min at 37°C in the absence (c) or in the presence of uPA (10 nM). Total cell extracts were analyzed
by Western blot using an anti-phosphorylated ERK (p-ERK1/2) and an anti-total ERK (tot-ERK2). (C) 325 peptide specifically blocks
uPA-mediated cleavage of uPAR. Cells were preincubated for 20 min at 37°C with 325 or s325 peptides (10 M) and incubated for 40 min
at 37°C in the absence (c) or in the presence of uPA (10 nM). Total cell extracts were deglycosylated and analyzed by Western blot using a
rabbit polyclonal anti-uPAR antibody. Positions of intact (uPAR) and cleaved (D2D3) uPAR are indicated. (D) 325 peptide does not block
SD2D3-induced migration of LB6 parental cells. Cells were preincubated for 20 min at 37°C with 325 or s325 peptides (10 M), and their
chemotactic responses were tested toward medium alone (c) or sD2D3 (1 nM). Random cell migration (c) of nonpretreated cells is referred
to as 100% of migration. Results are representative of three independent experiments.
Figure 8. hcr-uPAR/31 association is required to activate EGFR. UPAR and EGFR are constitutively associated. UPA-induced phos-
phorylation of EGFR, only seen in hcr-uPAR cells, is specifically blocked by addition of 325. After a 20-min pretreatment with 325 or s325
peptides (10 M), cells were stimulated with uPA (10 nM) for additional 20 min. EGFR was immunoprecipitated from total cell extracts with
an anti-EGFR antibody and blotted for uPAR and EGFR (A) or phosphotyrosine and EGFR (B). CE is a control cell extract and a negative
control used irrelevant immunoglobulin for immunoprecipitation (IP:IgG). (C) Extracts from wt- and hcr-uPAR cells, treated or not with 10
nM uPA, were immunoprecipitated with anti-3 antibody, and the precipitate was immunoblotted with anti-uPAR, anti-EGFR, or anti-
phosphotyrosine antibodies, as indicated.
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free to interact with 31 and EGFR. Because in LB6 cells
wt-uPAR does not associate with the EGFR and integrins in
the same complex, we must hypothesize that the uPA-in-
duced association between wt-uPAR and integrins may re-
sult in dissociation of wt-uPAR from the EGFR or in the
recruitment to the integrin only of EGFR-free uPAR. In
agreement with the immunoprecipitation data, although
disruption of the uPAR/integrin interaction with peptide
325 specifically prevented migration activated through
both forms of uPAR (Figure 3B), addition of an EGFR inhib-
itor only blocked hcr-uPAR-mediated migration (Figure 5A).
As we further dissected the pathway engaged by the two
forms of uPAR, we found that FPRL1 was only involved in
wt-uPAR chemotaxis because the desensitization experi-
ment with MMK1 peptide prevented the uPA-stimulated
migration of wt-uPAR but not that of hcr-uPAR cells (Figure
4A). In agreement with these results, pertussis toxin only
inhibited uPA-induced migration of wt-uPAR-expressing
cells (Figure 4B). Together, the results with MMK1 and
pertussis toxin not only confirm the involvement of FPRL1
in wt-uPAR-mediated migration but also rule out the in-
volvement of any GPCR in hcr-uPAR migration.
The uPAR/EGFR interaction was shown to be involved in
both cell migration (Jo et al., 2003) and tumor cell prolifera-
tion in vivo (Liu et al., 2002). It was also shown that uPAR-
mediated activation of the EGFR requires an intact uPAR
(Liu et al., 2002). A possible explanation of our results may
indeed involve uPAR cleavage. The extent of cleavage of
wt-uPAR by uPA or other proteinases may determine which
of the two adaptor proteins (FPRL1 versus EGFR) will be
engaged upon uPA binding to uPAR. However, activation
of FPRL1 via GPI-D2D3 was not demonstrated yet. What we
Figure 9. uPAR cleavage is required for
uPA-dependent ERK activation in wt-uPAR
cells. (A) Cells were treated with 10 nM uPA
for the indicated times or with 5 nM ATF for
1 h. Total cell extracts were analyzed by
Western blot using anti-phosphorylated ERK
(p-ERK1/2) and EGFR (p-EGFR), and anti-
total ERK (tot-ERK2) and EGFR (tot-EGFR)
antibodies. For the detection of full-length
and cleaved human uPAR, total cell extract
were first subjected to deglycosylation as de-
scribed in Materials and Methods. (B) wt-
uPAR-expressing cells were preincubated
with a cocktail of proteinase inhibitors (50
M ilomastat, 80 M E-64, 100 nM aprotinin,
and 100 mol/l amiloride) for 2 h and then
treated with 10 nM uPA for 40 min at 37°C.
Exogenous uPA failed to activate ERK in the
presence of the inhibitors.
Figure 10. Schematic representation of uPA-induced
pathways in wt- and hcr-uPAR cells. Scheme of the
signaling pathways activated by wt-uPAR (left) and
hcr-uPAR (right). (A) ERK activation via wt-uPAR
upon uPA binding and association to 31 and uPAR
cleavage. (B) FPRL1 engagement via wt-uPAR upon
uPA binding. (C) EGFR activation via hcr-uPAR upon
uPA binding and association to integrins and EGFR.
R. Mazzieri et al.
Molecular Biology of the Cell376
demonstrated, and which further support the central role
played by integrins, is that disruption of the uPAR/integrin
interaction with peptide 325 prevents wt-uPAR cleavage
mediated by uPA (Figure 7C). Moreover, in wt-uPAR-ex-
pressing cells, integrins (Figure 7B), but not FPRLI (Figure
7A), were also required for uPA-induced ERK activation,
and the ERK1/2 inhibitor PD98059 totally prevented uPA-
dependent chemotaxis of wt-uPAR, whereas it had no effect
on hcr-uPAR (Figure 6A). uPA-induced ERK activation was
also inhibited by a cocktail of protease inhibitors able to
block uPAR cleavage (Figure 9B), thus suggesting the re-
quirement of uPA-induced and integrin-mediated cleavage
of uPAR to activate ERK. Inhibition of ERK also inhibited
the basal migration of wt-uPAR-expressing cells (Figure 6A),
which show a higher basal level of activated ERK and a
higher random migration than parental LB6 cells or hcr-
uPAR-expressing cells (data not shown). The cleavage of
uPAR did not need to be carried out by uPA, because
wt-uPAR LB6 cells cleave uPAR in the absence of exogenous
uPA even though they do not express uPA (Figure 1C).
Moreover, catalytically inactive ATF also stimulates uPAR
cleavage in wt-uPAR cells (Figure 9A). This observation may
be of particular interest in the context of tumor invasion,
where several proteases, produced by tumor cells and/or
surrounding host cells, are known to play an important role
in tumor progression.
In conclusion our data show that uPAR can signal through
several types of transmembrane receptors upon “activation”
by several ligands and/or cleavage by different proteases.
This allows a broad range of combinations determined both
by the cell type induced to migrate and the surrounding
environment. Understanding the specificity and selectivity
of each combination will provide more direct and efficient
tools for the control of uPAR-mediated migration under
both physiological and pathological conditions such as tu-
mor growth and tumor invasion.
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